I like Genmab. The stock was one of my long positions for many years. I went into cash in the fall of 2021. After minus 40 percent, I will now gradually add to Genmab again.
I have sold all of my genmab shares i started to buy at the start of corona, 5 year tmeframe i think we see a head an shoulder formation an hoping to buy again 15-1600 kr :)
Hello again, i bought this stock last year at like 1500 kr, but unf. i see a Head an should forming in think it will fall a little back, of course i hope im wrong an go up from here :) An not selling holding at least 5-20 years :)
steamloss in the Genmab stock will likely fuel a new rush.
1) the 2 previous times times RSI has been below 30, it has resulted in strong returns. Will it happen a 3rd time?
2) The current strongly rising RSI will like make sure that the price will move and stay above the short term downward trend.
3) Opportunity for the price to move towards 2557 DKK. Yet be...
Some basic chart analysis on Genmab.
This is more to bring your attention to the stocks long term growth prospects.
With a TTM P/E ratio of 29 and a FWD of 3, combined with solid revenue growth TTM and FWD leads me to suggest that Genmab will thrive in the coming months and climb to all time highs.
GENMAB A/S
Our contribution has known a strong acceleration and impressive upward defense positive and still He is on a strong track and the prospect of purchase is still A fresh list of buyers' abundance and strong size
I've been reading through their studies to see what they're working on and what their proprietary info is being used for and it's actually impressive. Best part is that several of these studies are big on the public conscience, when one of these pops, I can easily see interest in this company peaking real quick.
Partnerships with several major companies: BNTX,...
November 4, 2020; Copenhagen, Denmark;
Interim Report for the First Nine Months Ended September 30, 2020
Highlights
Novartis granted U.S. FDA approval for Kesimpta® (ofatumumab) in relapsing multiple sclerosis
Janssen and European Myeloma Network achieved positive topline results from Phase 3 APOLLO study of daratumumab in relapsed or refractory multiple...
After the royalty issue with Janssen announced today we have seen a sudden decrease. I would say 2000 DKK is a buying zone/support level and it must be held if the stock price should rise to new ATH again.
Genmab AS (GMAB - NASDAQ) is in 4th subwave of 5th wave up, wait for one leg down to complete 4th subwave to get in to trade, from where it again resumes the up cycle. The invalidation level for 33.52, the high of 1st subwave.
